RANKL PRODUCTION INHIBITOR
The production of RANKL may be inhibited by orally ingesting a milk-derived basic protein. Thus, a RANKL production inhibitor containing a milk-derived basic protein fraction as an active ingredient; a therapeutic agent for a metabolic bone disease and a therapeutic agent for an immune disease each containing the RANKL production inhibitor; and a food/beverage and a feed each containing a specified amount of the RANKL production inhibitor and being characterized by inhibiting the production of RANKL have a remarkable effect of inhibiting the production of RANKL, can be ingested on a daily basis, and exhibit high safety even when being ingested over a long period.
1 . A RANKL production inhibitor, comprising a milk-derived basic protein fraction as an active ingredient.
2 . A therapeutic agent for a metabolic bone disease, comprising the RANKL production inhibitor according to claim 1 .
3 . A therapeutic agent for an immune disease, comprising the RANKL production inhibitor according to claim 1 .
4 . A food/beverage, comprising the RANKL production inhibitor according to claim 1 in an amount of 10 mg to 100 g/100 g based on a solid content.
5 . A feed, comprising the RANKL production inhibitor according to claim 1 in an amount of 10 mg to 100 g/100 g based on of a solid content.